Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: An 11-year experience from the FIN-RACo Trial.

 Renal safety of initial compounding versus azygos DMARD therapy in patients with primeval rheumatoid arthritis: An 11-year undergo from the FIN-RACo Trial.Krista Karstila et al.Clinical and empiric rheumatology 28 (1), 73-8info:pmid/20346242Posted by Terkko to rheumatoid arthritis on Thu Apr 01 2010 at 09:48 UTC | info | related